GlaxoSmithKline PLC ADR

Yahoo Finance • 24 hours ago

GSK To Acquire 35Pharma For $950 Mln

(RTTNews) - GSK plc (GSK, GSK.L, GS71.DE) has entered an agreement to acquire 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of protein-based therapeutics. GSK will acquire 100% o... Full story

Yahoo Finance • 2 days ago

Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report... Full story

Yahoo Finance • 6 days ago

Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading

Company Logo The nicotine gum market presents opportunities through rising anti-smoking campaigns, demand for convenient cessation solutions, flavored variants, and online channels. Innovations like lozenges enhance market position. Asia-... Full story

Yahoo Finance • 8 days ago

FTSE 100 Live: Index powers to new highs as inflation falls, defence in demand

FTSE 100 Live: Index powers to new highs as inflation falls, defence in demand Proactive uses images sourced from Shutterstock FTSE 100 climbs 92 points to 10,648 BAE Systems and Glencore lead risers after results Inflation eases to furth... Full story

Yahoo Finance • 8 days ago

Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035

Company Logo Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, boosting patient outcomes.... Full story

Yahoo Finance • 9 days ago

Mark Hillman's Strategic Move: Significant Addition to State Street SPDR S&P 500 ETF Trust

This article first appeared on GuruFocus. Insight into Mark Hillman (Trades, Portfolio)'s Fourth Quarter 2025 Investment Moves Warning! GuruFocus has detected 10 Warning Signs with WBD. Is WBD fairly valued? Test your thesis with our fre... Full story

Yahoo Finance • 10 days ago

Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program

Wave Life Sciences (NASDAQ:WVE) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, consensus sentiment around Wave Life Sciences (NASDAQ:WVE) remained strongly bullish. The stock received cover... Full story

Yahoo Finance • 11 days ago

GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17%

GSK plc (NYSE:GSK) ranks among the best undervalued European stocks to buy now. On February 4, GSK plc (NYSE:GSK) announced fourth-quarter earnings that outperformed analyst estimates in several important metrics. Earnings per share for th... Full story

Yahoo Finance • 13 days ago

Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells

By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts predicting... Full story

Yahoo Finance • 14 days ago

Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%

This article first appeared on GuruFocus. Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Warning! GuruFocus has detected 7 Warning Sign with C. Is C fairly valued? Test your thesis with our free DCF calcu... Full story

Yahoo Finance • 15 days ago

Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica

AstuteAnalytica India Pvt. Ltd. High-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers. The market is bifurcating, with innovation focused on severe phenotypes a... Full story

Yahoo Finance • 15 days ago

GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales

Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a year ago. The year-over-year decrease was... Full story

Yahoo Finance • 15 days ago

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to understand the path forward mRNA-1010 has been submitted and accepted for review in... Full story

Yahoo Finance • 16 days ago

GSK’s Arexvy RSV vaccine accepted for regulatory review in China for seniors

* GlaxoSmithKline (GSK [https://seekingalpha.com/symbol/GSK]) said on Tuesday that China’s Center for Drug Evaluation has accepted its regulatory application for Arexvy (RSV [recombinant, adjuvanted] vaccine) for review. The vaccine is i... Full story

Yahoo Finance • 17 days ago

Citi lifts GSK target price but keeps neutral stance after rally

Citi lifts GSK target price but keeps neutral stance after rally Proactive uses images sourced from Shutterstock Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sha... Full story

Yahoo Finance • 20 days ago

Why Analysts See GSK (LSE:GSK) Differently As The Fair Value Story Starts To Shift

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The fair value estimate for GSK has been nudged to £18.83 from £18.73, a small move that reflects... Full story

Yahoo Finance • 21 days ago

GSK (GSK) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, October 29, 2025 at 10 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Emma Walmsley Chief Commercial Officer — Luke Miels President, ViiV Healthcare — Deborah Waterhouse Chief Financi... Full story

Yahoo Finance • 21 days ago

BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration

LONDON, Feb. 5, 2026 /PRNewswire/ -- BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.The biopharmaceutical industry’s most trus... Full story

Yahoo Finance • 22 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were trending higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 22 days ago

GSK Q4 Earnings Call Highlights

GSK logo Key Points GSK reported 2025 sales up 7% at CER to over £32bn, with core operating profit +11%, core EPS +12%, free cash flow of ~£4.0bn (＞£5.0bn ex‑Zantac) and an increased dividend of 66p. For 2026 the company guided sales of... Full story